Sep 25th 2012 - Edison Investment Research today published a report on Sucampo Pharmaceuticals entitled "Prostone Pioneer". In summary, the report says:
Sucampo’s investment case rests on its ability, with its partner Takeda, to protect and boost sales of constipation drug Amitiza (lubiprostone) in the US in the face of fresh competition from Ironwood/Forest’s Linzess (linaclotide). The entrance of Linzess in Q412 and a reinvigorated promotional effort behind Amitiza should help to grow the US market for the use of prescription drugs to treat constipation disorders (currently just 6-8%), while Amitiza’s proven track record provides a key differentiating factor.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »